Processa Pharmaceuticals Inc

Research Processa Pharmaceuticals Inc (PCSA) on Bullrun: market cap USD 5.84M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 5.84M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 13.56M-USD 12.24Mn/a-10.36USD 5.54MUSD 0USD 5.58M
FY2024USD 0-USD 11.85M-USD 11.25Mn/a-96.78USD 1.19MUSD 73.51KUSD 1.70M
FY2023USD 0-USD 11.12M-USD 8.07Mn/a-8.48USD 4.71MUSD 150.55KUSD 4.99M
FY2022USD 0-USD 27.42Mn/an/a-34.05USD 6.50MUSD 31.21KUSD 7.47M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 5.84Mn/an/an/a
20252025-12-31USD 6.53Mn/an/an/a
20242024-12-31USD 3.27Mn/an/an/a
20232023-12-29USD 8.26Mn/an/an/a
20222022-12-30USD 17.60Mn/an/an/a
20212021-12-31USD 76.93Mn/an/an/a

About Processa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Processa Pharmaceuticals Inc's market cap?

Processa Pharmaceuticals Inc's market capitalization is USD 5.84M.

What does Processa Pharmaceuticals Inc do?

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.